（UPA）Ulipristal Acetate raw material, as a selective progesterone receptor modulator, can control the growth of hysteromyoma, reduce symptoms, and can be used continuously for a long time, which brings new hope for drug treatment of hysteromyoma.
1. Estrogen, progesterone, and their receptors play an important role in the growth of uterine leiomyoma.
In the past, we believed that estrogen is the main factor to stimulate the growth of uterine leiomyoma. Estrogen can trigger a rapid membrane start signal transduction pathway, and directly change the level of the second messenger in the signal transduction pathway without regulating gene transcription.
Recent studies have found that the distribution of progesterone receptor (PR) in uterine leiomyoma is much higher than that in the normal uterine muscle layer. In addition, a large number of clinical studies have also confirmed that progesterone and its receptors promote the growth of uterine leiomyoma.
Progesterone can regulate the gene expression of growth factor-related pathway proteins and affect genes related to cell proliferation and apoptosis. The combination of progesterone and receptor can quickly activate the PI3K/AKT pathway, which is considered to be one of the main mechanisms of abnormal growth of uterine leiomyoma.
2. Pharmacological mechanism of HRP 2000.
The mechanism of EllaOne powder in the treatment of uterine leiomyoma is not yet clear, but the preliminary conclusions obtained from basic research may include the following two points: ① UPA stimulates the expression of matrix metalloproteinase-2, induces collagen degradation, and reduces the size of uterine leiomyoma. ② UPA inhibits activin A, thereby regulating the mRNA expression of fibronectin and vascular endothelial growth factor A, and inhibiting the proliferation of uterine leiomyoma cells.
3. How do we evaluate such products?
Although the research on this mechanism is still incomplete, selective progesterone receptor modulators (SPRMs) are synthetic drugs. These drugs have a strong affinity with PR, and they can both stimulate PR and antagonize PR when combined with PR.
There are four types of representative drugs of SPRMs used clinically: Mifepristone, 319460-85-0 Axitinib, Ulipristal Acetate, and 198414-31-2 telapristone acetate, which have entered the clinical trial stage, and have preliminarily confirmed their effects on reducing the size of fibroids and improving the symptoms of uterine bleeding. 99% purity Ulipristal Acetate raw powder is a hot research topic abroad. Compared with progesterone receptor antagonists such as 84371-65-3 mifepristone, SPRMs are more selective and have less effect on glucocorticoid receptors.
The information in this article comes from the Internet and is not used as treatment advice or investment advice. If this article has an impact on your rights and interests or is interested in this product, please contact us in time so that we can provide you with more help